Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.


TSXV:MIR - Post by User

Bullboard Posts
Comment by littleguy21on Jul 06, 2012 2:15pm
168 Views
Post# 20089645

RE: More sales coming shortly

RE: More sales coming shortly
MedMira Ships 400,000 Tests to China and Receives Follow-on Order

HALIFAX, July 13, 2011 /CNW/ - MedMira Inc., ("MedMira") (TSXV: MIR) (NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, today announced that it has completed and shipped the order for 400,000 rapid HIV tests placed by its strategic partner in China, Triplex International Biosciences Co., Ltd. (Triplex), in April 2011.

"The fulfillment of this initial order for Triplex went very smoothly," said Hermes Chan, CEO, MedMira Inc. "The Triplex sales strategy in the new China healthcare sector is working very well, with the number one ranking of our test in a recent evaluation by the China National Center for Disease Control (China CDC) being a key marketing tool in many of their initiatives."

Triplex has placed a follow-on order for MedMira rapid HIV tests as it continues to pursue sales opportunities in the outreach clinics and hospital laboratory vertical markets in the high growth rapid diagnostics market within China's restructured healthcare system.

Maybe since its been a year we will see that follow up order around the same time of year.??

 

Bullboard Posts